

FORM PTO 3449, Adapted

LIST OF INFORMATION DISCLOSED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.
8805.105001SERIAL NO.
09/922,011FILING DATE
August 2, 2001APPLICANT
Svetlana A. DambinovaGROUP
1647

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						

RECEIVED
FEB 10 2003
TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	NAME	TRANSLATION YES NO.
AK				
AL				
AM				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

RBK	AN	Gusev et al.; "Investigation of the Level of Autoantibodies to Glutamate Receptors in Blood Serum of Patients in Acute Period of Ischemic Stroke;" Zhurnal Nevrologii I Psikhiatrii Imeni S. S. Korsakova; Vol. 96, No. 5; 1996; Pages 68-72; XP002212398; Abstract
RBK	AO	Hess et al.; "Cloning and Functional Characterization of Human Heteromeric N-Methyl-D-Aspartate Receptors;" Journal of Pharmacology and Experimental Therapeutics, American Society for Pharmacology and, US, Vol. 278; No. 2; 1 August 1996; pages 808-816; XP000676640; ISSN: 0022-3565; Abstract
RBK	AP	Monyer et al.; "Heteromeric NMDA Receptors: Molecular and Functional Distinction of Subtypes;" Science; 22 May 1992; Vol. 256; No. 5060; Pages 1217-1221; ISSN: 0036-8075; XP001093645; Abstract
RBK	AQ	Skoromets et al.; "Autoantibodies to NMDA-receptor fragment in patents with ischemic stroke;" Journal of the Neurological Sciences; Vol. 150; (1997); Page S280; XP001098449; Abstract

EXAMINER

Rahul B. Karmat

DATE CONSIDERED

12/2/03


EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet **1** of **2**

Complete if Known

Application Number **09/922,011**
Filing Date **August 2, 2001**
First Named Inventor **Dambinova, Svetlana A.**
Group Art Unit **1614**
Examiner Name
Attorney Docket Number **08805.105001**

RECEIVED
FEB 01 2002
TECH CENTER 1600/2900
FEB 26 2002

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number	Kind Code ² (if known)				

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
RBK	CA	Dambinova, et al., "Autoantibodies to Subtypes of Glutamate Receptors as a Hallmarks of Brain Damage: Diagnostic Significance for Paroxysmal Activity and Ischemia." <i>Journal of Higher Nervous Activity</i> . 1997. Vol. 47 (2), pp. 151-156.	
RBK	CB	Gusev, et al., "Neuroprotective Effects of Glycine for Therapy of Acute Ischaemic Stroke." <i>Cerebrovasc Dis</i> 2000; 10:49-60.	
RBK	CC	Gahring, et al., Autoantibodies to Neuronal Glutamate Receptors in Patients with Paraneoplastic Neurodegenerative Syndrome Enhance Receptor Activation." <i>Molecular Medicine</i> , Volume 1, Number 3, March 1995, 245-253.	
RBK	CD	Rogers, S.W., "Autoantibodies to Glutamate Receptor GluR3 in Rasmussen's Encephalitis." <i>Ovid: Science</i> , Volume 265(5172), 29 July 1994, pp. 648-651.	
RBK	CE	Dambinova, et al., "Monitoring of Brain Spiking Activity and Autoantibodies to N-Terminus Domain of GluR1 Subunit of AMPA Receptors in Blood Serum of Rats with Cobalt-Induced Epilepsy." <i>Journal of Neurochemistry</i> , Lippincott-Raven Publishers, Philadelphia.	

Examiner Signature	Ramuel B. Karpov	Date Considered	12/2/03
-----------------------	-------------------------	--------------------	----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

Approved for use through 10/31/2002. PTO FORM 08A (08-00)
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	09/922,011
Filing Date	August 2, 2001
First Named Inventor	Dambinova, Svetlana A.
Group Art Unit	1619
Examiner Name	
Attorney Docket Number	08805.105001

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
RBK	CF	Dambinova, et al., "The presence of autoantibodies to N-terminus domain of GluR1 subunit of AMPA receptor in the blood serum of patients with epilepsy." <i>Journal of Neurological Sciences</i> , 152 (1997) 93-97. ✓	
	CG	Vincent, et al., "Pathogenic autoantibodies to neuronal proteins in neurological disorders." <i>Journal of Neuroimmunology</i> , 100 (1999) 169-180. ✓	
	CH	Lipton, et al., Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor." <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 94, pp. 5923-5928, May 1997. ✓	
	CI	Meldrum, B.S., "Glutamate as a Neurotransmitter in the Brain: Review of Physiology and Pathology ¹ ." <i>Journal of Nutrition</i> . 2000; 130:1007S-1015S. ✓	
	CJ	Dávalos, et al., "Neurological Deterioration in Acute Ischemic Stroke: Potential Predictors and Associated Factors in the European Cooperative Acute Stroke Study (ECASS) 1." <i>Ovid: Davalos: Stroke</i> , Volume 30(12), December 1999, 2631-2636. ✓	
	CK	Davalos, et al., "Duration of Glutamate Release After Acute Ischemic Stroke." <i>Ovid: Davalos: Stroke</i> , Volume 28(4), April 1997, 708-710. ✓	
	CL	Castillo, et al., "Neuroexcitatory Amino Acids and Their Relation to Infarct Size and Neurological Deficit in Ischemic Stroke." <i>Ovid: Castillo: Stroke</i> , Volume 27(6), June 1996, 1060-1065. ✓	
	CM	Yamamoto, et al., "CSF and ECF Glutamate Concentrations in Head Injured Patients." <i>Acta Neurochir</i> (1999) [Suppl] 75:17-19. ✓	
	CN	Castillo, et al., "Progression of ischaemic stroke and excitotoxic aminoacids." <i>Lancet</i> 1997; 349: 79-83. ✓	
	CO	Gusev, et al., "The level of autoantibodies to glutamate receptors in the blood serum of patients in the acute period of ischemic stroke." <i>Ovid Technologies, Inc.</i> , 2000-2001, Version rel4.5.0, SourceID 1.5686.1.73. (Abstract) ✓	✓
	CP	Vila, et al., "Plasma homocysteine levels in patients with ischemic cerebral infarction." <i>Med Clin (Barc)</i> 1998 May 9; 110(16): 605-8. (Abstract) ✓	✓
RBK	CQ	Hill, et al., "Biochemical markers in acute ischemic stroke." <i>Canadian Medical Association Journal</i> , April 18, 2000; 162:1139-40. ✓	

Examiner Signature	Ramuel B. Kapur	Date Considered	12/2/03
--------------------	-----------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.